Skip to main content

Nephropathy News

Calliditas Therapeutics Announces Full FDA Approval of Tarpeyo, the Only FDA-Approved Treatment for IgA Nephropathy to Significantly Reduce the Loss of Kidney Function

December 20, 2023 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) ...

FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy

STOCKHOLM, Dec. 15, 2021 /PRNewswire/ – Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

lisinopril, methylprednisolone